Weight loss is a common challenge faced by people around the globe. Achieving and maintaining a healthy weight requires strong determination and a strategic approach. This article provides actionable tips to help individuals effectively reduce their weight. Tips for Weight Loss Stay Active: To lose weight, it is crucial to avoid a sedentary lifestyle. Incorporating […]
Zealand Pharma A/S (Nasdaq: ZEAL), a pioneer in peptide-based drug development, has shared topline results from its DREAM trial, evaluating the efficacy of low doses of the GLP-1/GLP-2 receptor dual agonist, dapiglutide, in treating obesity. This clinical study marks a significant step forward in understanding the potential of dapiglutide to induce weight loss without lifestyle […]
In a significant development in the field of obesity treatment, Lilly’s Zepbound (tirzepatide) has shown remarkable results in the SURMOUNT-4 study. Published in The Journal of the American Medical Association (JAMA), the study details how Zepbound injection led to superior mean percent changes in body weight compared to placebo among adults with obesity or overweight, […]
Roche announced its definitive agreement to acquire Carmot Therapeutics, Inc., based in Berkeley, California, for an upfront purchase price of USD 2.7 billion, with additional milestone payments of up to USD 400 million. Carmot Therapeutics’ Incretin Portfolio: A Boon for Obesity Treatment The acquisition provides Roche access to Carmot Therapeutics’ innovative portfolio of incretins, which […]
Pfizer Inc. (NYSE: PFE) has announced encouraging topline data from its Phase 2b clinical trial (NCT04707313) investigating danuglipron, an oral Glucagon-like peptide-1 receptor agonist (GLP-1RA), in adults with obesity but without type 2 diabetes. The study successfully met its primary endpoint, showing a statistically significant change in body weight from baseline. Effective Weight Reductions Observed […]
The U.S. Food and Drug Administration has granted approval to Eli Lilly’s Zepbound (tirzepatide) injection, making it the only obesity treatment that activates both GIP and GLP-1 hormone receptors. This medication is tailored for adults with obesity or overweight conditions associated with weight-related medical issues such as hypertension and type 2 diabetes. Zepbound is recommended […]
Biocon Limited, the innovation-driven global biopharmaceutical frontrunner, has made headlines by sealing a significant partnership agreement with Juno Pharmaceuticals, Canada’s esteemed specialty pharmaceutical giant. This collaboration aims at the commercialization of Liraglutide, a sophisticated drug-device formulation. This game-changing combination has been curated for the proficient treatment and management of challenges like Type 2 diabetes and […]
Novo Nordisk, a global leader in healthcare, has acquired Embark Biotech, including its lead metabolic program, in a deal that further strengthens its portfolio in obesity and related co-morbidities treatment. Alongside the acquisition, the two companies have announced a three-year research and development (R&D) collaboration to discover and develop new pharmaceutical solutions for obesity and […]
Sugar Watchers, a burgeoning health brand specializing in Low Glycemic Index (Low GI) staples, has successfully raised INR 3.6 crores in a recent funding round led by ah! Ventures. Notably, the round also saw investments from The Chennai Angels, Mumbai Angels, Keiretsu Forum, Chandigarh Angels, and Sanjiv Rangrass, ex-ITC board member. Sugar Watchers aims to […]
In a move marking a significant expansion in the biopharmaceutical sector, Eli Lilly and Company (Lilly) has successfully completed the acquisition of Versanis Bio, a clinical-stage biopharmaceutical player founded by Aditum Bio in 2021. This strategic acquisition sets the stage for Lilly to delve deeper into pioneering treatments for cardiometabolic diseases, including obesity. Central to […]